JBIO
The table below shows Jade Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $36.05M | $22.01M | $22.55M | $20.02M | $13.58M | $21.25M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.39M |
| $5.39M |
| $5.23M |
| $3.36M |
| $1.38M |
| $4.92M |
| Operating income | -$43.45M | -$27.40M | -$27.78M | -$23.38M | -$14.96M | -$26.16M |
| Income tax | $16.00K | $0.00 | $0.00 | - | $0.00 | - |
| Net income | -$40.37M | -$25.18M | -$32.13M | -$38.17M | -$16.28M | -$24.77M |
| EPS (diluted) | -$0.57 | -$0.48 | -$0.86 | -$12.10 | -$5.16 | -$0.86 |